12:00 AM
 | 
Mar 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PMX53: Development discontinued

Arana discontinued development of PMX53 for ocular indications after observing insufficient levels of activity in preclinical models of AMD. The...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >